|
Pluristem secures grant for R&D
June 2012
SHARING OPTIONS:
HAIFA, Israel—Pluristem Ltd., a wholly owned subsidiary of
Pluristem
Therapeutics Inc., announced last month that it has gained approval
for a $3.1-million grant from the Office of the Chief Scientist within the
Israeli Ministry of
Industry, Trade and Labor. The grant will cover research
and development expenses from March to December 2012, and Pluristem is required
to pay
royalties at a rate of 3 to 5 percent on sales of products and services
resulting from technology developed using all OCS grants until 100 percent of
the dollar-linked grants amount plus interest are repaid.
"We are pleased Pluristem's PLX cells
were recognized as an
innovative state-of-the art technology with a potential to create long-term
sustainable competitive advantage in the cell therapy
industry," said Zami
Aberman, chairman and CEO of Pluristem. Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|